Table 2.
Selectivity of AE9C90CB, tolterodine, oxybutynin, solifenacin and darifenacin at human recombinant muscarinic receptor subtypes
| Compound | Fold selectivity | |||
|---|---|---|---|---|
| M1/M3 | M2/M3 | M4/M3 | M5/M3 | |
| AE9C90CB | 2 | 20 | 3 | 3 |
| Tolterodine | 1 | 1 | 1 | 0.4 |
| Oxybutynin | 2 | 5 | 1 | 8 |
| Solifenacin | 1 | 4 | 8 | 3 |
| Darifenacin | 13 | 25 | 20 | 5 |
Fold selectivity is antilog of the difference between pKi at muscarinic M3 receptors and those at M1, M2, M4, M5 subtypes.